LOGAN CAROLYN J 4
4 · SALIX PHARMACEUTICALS LTD · Filed Jul 2, 2012
Insider Transaction Report
Form 4
LOGAN CAROLYN J
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2012-06-28$52.07/sh−119,300$6,211,832→ 644,488 total - Exercise/Conversion
Common Stock
2012-06-28$4.07/sh+228,467$929,861→ 763,788 total - Exercise/Conversion
Option to Buy Common Stock
2012-06-28−228,467→ 0 totalExercise: $4.07Exp: 2012-07-01→ Common Stock (228,467 underlying)
Holdings
- 400,000(indirect: by GRAT)
Common Stock
- 44,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (44,000 underlying) - 33,750
Option to Buy Common Stock
Exercise: $7.60Exp: 2013-07-24→ Common Stock (33,750 underlying) - 65,625
Option to Buy Common Stock
Exercise: $18.87Exp: 2014-06-17→ Common Stock (65,625 underlying) - 33,750
Option to Buy Common Stock
Exercise: $18.87Exp: 2014-06-17→ Common Stock (33,750 underlying)
Footnotes (2)
- [F1]The shares covered by this Form 4 were acquired upon exercise of a stock option that was to expire in July 2012. Ms. Logan only sold enough of these shares to pay the exercise price and the related taxes. This sale was pursuant to a Rule 10b5-1 Sales Plan dated December 9, 2011, which is intended to comply with Rule 10b5-1.
- [F2]Options are 100% vested.